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Summary The effects of certain compounds on the in vitro growth rate and the sensitivity to doxorubicin of
P388 murine leukaemia cell line and of a doxorubicin-resistant subline (P388/ADR) were studied.
The calcium channel blocking activity of these compounds was evaluated by measuring their effects on the
sodium-dependent and membrane potential-dependent calcium uptake in synaptic plasma membrane vesicles.
At non-inhibitory concentrations, verapamil, dipyridamole, meclizine and nicardipine were highly active in
restoring the sensitivity to doxorubicin of P388/ADR cells. Moderately active were propranolol, N-(,B-
diethylaminoethyl)-N-(,B-hydroxy-,B-phenylethyl)-2, 5-dichloranaline (MDL-6792), thioridazine and chlorocycli-
zine, while nifedipine, guanethidine, phentolamine, chloroquine and papaverine had zero or only minimal
synergistic activity to doxorubicin in this cell line. Doxorubicin synergistic activity could not be demonstrated
in the parent drug-sensitive cell line.
No sodium-dependent or membrane potential-dependent calcium uptake could be demonstrated in vesicles
prepared from plasma membranes of either cell line. There is no correlation between the ability of these
compounds to inhibit calcium uptake in synaptic vesicles and their potency in restoring the sensitivity of
P388/ADR cells to doxorubicin.
Treatment of cancer patients with combinations of
cytotoxic drugs has been shown, in many instances,
to be more effective than single drug regimens, in
controlling the disease. In recent years a number of
investigators have shown in experimental systems
that certain compounds that are not used as
anticancer agents but rather for the treatment of
other medical problems, enhanced the activity of
certain anticancer drugs. Such compounds include
some coronary vasodilators, tranquillizers,
antifungal frugs, local anaesthetics and even surface
active compounds used as pharmaceutical aids
(Mizuno & Ishida, 1982a,b, c; Tsuruo et al.,
1982,1983a, b; Ganapathi & Grabowski, 1983;
Inaba et al., 1981; Ozols et al., 1983; Medoff et al.,
1975; Valeriote et al., 1979; Klein & Frayer, 1978;
Carlsen et al., 1976; Chlebowski et al., 1982; Riehm
& Biedler, 1972; Bown & Goldman, 1975; Seeber et
al., 1982).
Recently, such synergism has been demonstrated
between doxorubicin and compounds known either
to have calcium channel blocking activity, or
inhibitory activity of calmodulin mediated effects
(Tsuruo et al., 1982,1983a; Ganapathi &
Grabowski, 1983). Although calcium levels were
not measured in these studies, Tsuruo et al.
(1982,1983a), suggested that the cellular calcium
environment plays an important role in the
manifestation of this synergism by controlling the
efflux of the drug from the cells.
We have recently reported that perhexiline
maleate enhances the uptake and the cytotoxic
activity of doxorubicin, in a doxorubicin-resistant
subline of P388 leukaemia cells but not in the
parent drug-sensitive cell line (Ramu et al., 1984b).
This activity of perhexiline was not inhibited by
increasing the concentration of calcium in the
medium or by adding a calcium ionophore. Nor
could it be imitated by reducing the concentration
of the calcium in the medium, chelating the
medium's calcium with ethyleneglycol bis (f,-
aminoethyl ether)-N,N'-tetraacetic acid (EGTA), or
by blocking, with lanthanum ions, the uptake of
calcium into the cells. Therefore, although
perhexiline maleate was shown to act as a calcium
channel antagonist in exitable tissues (Fleckenstein,
1977), it was suggested that its ability to enhance
the cytotoxicity of doxorubicin in our system was
unrelated to calcium antagonism. In the present
study we report on the restoration of doxorubicin
responsiveness in the doxorubicin-resistant P388
cells by some other drugs, not related to perhexiline
and provide evidence that their effects are also
unrelated to a calcium antagonistic activity.
Materials and methods
Cell culture
P388 murine leukaemia cells and a subline resistant
to doxorubicin (P388/ADR), were propagated
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continuously in suspension culture as previously
described (Ramu et al., 1984b). Cells were grown in
RPMI 1640 medium (Grand Island Biological Co.,
Grand Island, N.Y.) supplemented with 10% heat-
inactivated foetal calf serum (Grand Island
Biological Co.), 10pM 2-mercaptoethanol (Sigma
Chemical Co., St. Louis, Mo.), 50unitsml-1
penicillin base and 50 ugml-1 streptomycin base
(both from Grand Island Biological Co.). Cell
growth was assessed by measurement of cell density
in a Coulter Counter (Coulter Electronics Ltd.,
Harpenden, Hertfordshire, UK). An inoculum of
cells was transferred to fresh medium once every 4
days to maintain growth in the exponential phase.
Initial cell density was I05cellsml-1 and after 4
days in culture it was 1-2 x 106cellsml-1. Cell
growth rates were calculated from the culture
densities measured once a day for 4 days.
Determination ofdrug sensitivity
The sensitivity of a cell line to a given drug or a
drug combination was assessed as follows: cells
were cultured in the presence of various drug
concentrations for 4 days and the slope of the log
cell density versus time plot was calculated by linear
regression analysis. The growth rate at each drug
concentration was expressed as the percentage of
the control growth rate. Dose-effect curves were
thus produced and were used to determine the
concentration of drug effective in inhibiting the
growth rate by 50% (ED50). The doxorubicin ED 5 for the drug-sensitive and the drug-resistant cell
lines ranged from 2-6 x10-8M and from 1-
2 x 10-6M respectively. No change in drug
sensitivity of either cell line was observed during 4
years of continuous in vitro culture.
Measurements of sodium-dependent and membrane
potential-dependent calcium uptake in synaptic
plasma membrane vesicles
Synaptic plasma membrane vesicles were isolated
from brain tissue of 14 day old rats as described by
Rahamimoff & Spanier (1979). Plasma membrane
vesicles were also prepared from 109 P388 cells and
from its doxorubicin-resistant subline.
Mitochondrial contamination of the vesicle
preparations was determined by measuring the
specific activity of glutamic acid dehydrogenase as
described by Erdreich et al (1983). This
contamination was found to be < 10%.
Calcium transport studies were done on vesicles
pre-equilibrated by incubation at 370C with a
solution containing either 0.15 MNa phosphate
buffer, pH 7.4, or 0.15MK phosphate buffer, pH
7.4. The loaded vesicles were concentrated by
centrifugation at 27,000g for 20min and suspended
into a small amount of the same solution. Ionic
gradients were formed by diluting 3pl of these
vesicles (about 30pg protein), into 250pl of
medium containing: 0.15 MKCl, 0.01M tris buffer
pH 7.4 or 0.3 M sucrose, 0.01 M tris buffer pH 7.4
and 504uM 45CaC12 (0.1 pCi). The reaction was
terminated after 5min by rapid filtration through
BA85-0.45pM Schleicher and Schuell filters,
followed by two washes of the filter with
0.15MKCI. The filters were dried and counted in a
liquid scintillation counter. Zero time counts were
done and subtracted from the results obtained.
To determine the effects of the tested compounds
on the calcium uptake, the drugs were added to the
incubation medium at the concentrations specified
and the calcium uptake was measured as described
above. The effects were immediate and did not
require any preincubation with the vesicles.
Drugs
Received as a gift were: N-(fl-diethylaminoethyl)-N-
(fl-hydroxy-fl-phenylethyl)-2, 5-dichloranaline (MDL
6792) From Dr W.J. Hudak of Merrell Dow
Pharmaceuticals, Cincinnati, Ohio; Verapamil from
Dr R. Kretzschmar of Knoll AG, Ludwigshafen,
West Germany; dipyridamole from Dr J.H. Shelley
of Boehringer Ingelheim Zentrale, Ingelheim am
Rhein, West Germany; thioridazine from Dr M.
Stolar of Taro Pharmaceutical Industries, Haifa
Bay, Israel; chlorocyclizine from Dr D. Ladkani of
Teva Pharmaceutical Industries, Jerusalem, Israel.
Results
A number of compounds were tested for synergistic
activity to doxorubicin in P388 and P388/ADR cell
cultures. In these experiments cells of both lines
were exposed to each one of the tested compounds
at a number of concentrations, either in the absence
or in the presence of a non-inhibitory concentration
of doxorubicin (10-8M for p388 cells and
3 x 10-7M for P388/ADR cells) and the effects on
growth rate measured. The ED50s of compounds
having any synergistic activity to doxorubicin in
P388/ADR cells are shown in Table I. The results
obtained with nifedipine, an analogue of
nicardipine, and with papaverine, a drug having
pharmacological acticities similar to dipyridamole
and verapamil, were also included in this table. In
the presence of the noninhibitory concentration of
doxorubicin, the ED 5 of the tested compounds in
P388/ADR cells was lowered to a variable extent
(up to 50 fold). In the parent doxorubicin-sensitive
cell line there was either zero or only minimal
synergistic cytotoxicity (the drug's ED50 was
lowered in the presence of subinhibitory
concentration of doxorubicin by less than 2 fold)REVERSAL OF RESISTANCE TO DOXORUBICIN 503
Table I The effect of 3 x 10-7M doxorubicin on




Guanethidine 3.7 x 10-4 2.3 x 10-4
Propranolol 1.5 x 10-4 3.0 x 10-I
Phentolamine 1.4 x 10-4 1.2 x 10-4
Verapamil >1 x 10-4 2.0 x 10-6
Nifedipine >6x 10-5 4.4x 10-5
Nicardipine 2.3 x 10-5 1.5 x 10-6
Dipyridamole 3.0 x 10-5 4.5 x 10-6
Chloroquine 2.1 x 10- 5 1.7 x 10-5
Chlorocyclizine 2.1 x 10- 9.2 x 10-6
Meclizine 2.7 x 10-5 2.3 x 10-6
Papaverine 1.7x10- 1.7x10-5
MDL 6792 2.4x 10-5 5.9x 10-6
Thioridazine 4.4 x 10-6 1.5 x 10-6
(data not shown). Details of such an experiment
carried with dipyridamole are presented in Figure 1.
In the absence of doxorubicin, dipyridamole up to
a concentration of 2 x 105M failed to inhibit the
growth of the P388/ADR cells. However, when a
subinhibitory concentration of doxorubicin was
added, a clear dose-dependent cytotoxic effect of
dipyridamole was observed. This combined drug





















Figure 1 The effects of dipyridamole on the growth
rate of P388/ADR cells in the absence (open bars) and
presence (solid bars) of 3 x 10- 7M doxorubicin.
concentrations well below those having an
independent growth-inhibitory effect of their own.
In order to characterize further the enhancement
of doxorubicin inhibition of growth by
dipyridamole, we measured the effects of increasing
concentrations of doxorubicin on the growth rate
of both cell lines in the presence of a non-inhibitory
concentration (10-5M) of dipyridamole (Figure 2).
In the presence of dipyridamole there was a marked
increase in the sensitivity of P388/ADR cells to
doxorubicin. The ED50 was reduced from
9.6 x 10-7M in the absence of dipyridamole to
6.3 x 10-8M in its presence. On the other hand, the
sensitivity of P388 cells to doxorubicin was only
minimally affected (ED50 reduced from









Figure 2 The sensitivity of P388 (0,0) and
P388/ADR (A, A) cells in the absence (closed
symbols) and presence (open symbols) of 1 x 10 5M
dipyridamole.
The effects of other compounds, at sub-inhibitory
concentrations on the sensitivity of the P388/ADR
cell line to doxorubicin are shown in Table II.
From the data presented in this table as well as
from those presented in Table I, it seems that the
compounds tested can be divided into 3 groups
according to their doxorubicin synergistic activity in
P388/ADR cells: (i) Highly active compounds for
which the ED50 is lowered 6 fold or more in the
presence of 3 x 107M doxorubicin and/or the
doxorubicin ED50 is lowered by 6 fold or more by
a non-inhibitory concentration of the compound.
This group includes verapamil, dipyridamole,
meclizine and nicardipine. (ii) Compounds with
intermediate activity, in which the ED 5 is lowered
by 2-5 fold in the presence of 3 x 10 7M
doxorubicin and/or the doxorubicin ED 5 is
lowered by 2-5 fold by a non-inhibitory
concentration of the compound. This group
includes propranolol, MDL 6792, thioridazine and
chlorocyclizine. (iii) Compounds with minimal or
zero activity. These include nifedipine,
guanethidine, phentolamine, chloroquine and
papaverine.
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Table II The effect of subinhibitory
concentrations of synergistic compounds on the





Chloroquine lx 1-5M 6.7x 10-7
Phentolamine I x 10-5M 5.6x 10-7
Propranolol I x 10-5M 3.9x 10-7
Chlorocyclizine 1 x 10-5M 3.3 x 10-7
MDL 6792 1 x 10-5M 2.7 x10-7
Dipyridamole 1 x 10-5M 6.1 x 10-8
Nicardipine 3 x 10-6M 3.0 x 10-7
Nifedipine 3 x 10-6M 1.8 x 10-6
Thioridazine I x 10-6M 4.4 x 10-7
It has recently been shown that certain bi- and
tri-valent inorganic cations as well as verapamil and
dihydropyridine compounds have a calcium channel
blocking activity in excitable tissues (Lee & Tsien,
1983; Reuter, 1983). Other studies have also shown
that lanthanum and verapamil can block the
potential-dependent and sodium-dependent
movements of calcium across the membrane of
isolated brain synaptosomes (Erdreich et al., 1983;
Gill et al., 1981; Nachshen & Blaustein, 1979). We
therefore examined whether in addition to
verapamil, the other compounds, screened in this
study for synergism to doxorubicin, can also block
the calcium uptake into isolated synaptosomes. The
inhibition of the sodium-dependent and membrane
potential-dependent calcium uptake, obtained by
these compounds, is shown in Table III.
An appreciable uptake of calcium could not be
obtained in sodium phosphate or potassium
phosphate loaded membrane vesicles prepared from
either cell line.
Discussion
Dopyridamole was found in the present study to be
highly potent in restoring the sensitivity of
P388/ADR cells to doxorubicin (Figures 1 and 2).
In previous studies, some of the pharmacological
activities of dipyridamole were related to its ability
to block adenosine uptake (Liu & Feinberg, 1973;
Born & Mills, 1969). Inhibition of adenosine uptake
was also recently reported for phenothiazines like
thioridazine (Phillis & Wu, 1981). However,
papaverine and nitrobenzylthioinosine, which are
also effective inhibitors of adenosine uptake (Born
& Mills, 1969; Lauzon & Paterson, 1977), do not
have doxorubicin synergistic activity (Table I and
Ramu et al., 1984a). We therefore suggest that the
doxorubicin synergistic effect of dipyridamole is not
related to its ability to block adenosine transport.
The data presented in this study (Tables I and II)
indicate that dipyridamole, verapamil and
nicardipine have similar potencies in restoring the
sensitivity of P388/ADR cells to doxorubicin.
Previous experiments in excitable tissues have
demonstrated that verapamil and nicardipine can
block the cell membrane calcium channels (Triggle,
1982). However, such an activity could not be
demonstrated for dipyridamole (Table III and
Mustafa & Nakagawa, 1983). The inability of
dipyridamole to block the sodium-dependent or the
membrane potential-dependent calcium uptake in
synaptic plasma membrane vesicles suggests that
the synergism of these compounds with doxorubicin
in the drug-resistant P388 cells is not related to
calcium channel blocking activity. This suggestion
is further supported by the findings that in plasma
membrane vesicles, prepared from either P388 or
P388/ADR cells, no sodium-dependent or
membrane potential-dependent calcium uptake
could be demonstrated. Furthermore, Toll (1982)
has recently demonstrated that the calcium channel
blocking activity in exitable membranes, by calcium
Table III Inhibition of sodium-dependent (A) and membrane
dependent (B) calcium uptake in synaptic plasma membrane
vesicles
% Inhibition % Inhibition
Concentration ofA ofB
Lanthanum 5pM 19.9 0
Lanthanum 50pM 83.4 58.0
Perhexiline 100PM 87.1 73.7
Chlorocyclizine 1OOpM 55.5 48.5
Chloroquine 100pM 44.6 49.6
Phentolamine 100pM 35.1 39.0
Guane,thidine 100pM 36.4 42.4
Verapamil 100pM 25.8 19.4
Dipyridamole 100pM 0 0REVERSAL OF RESISTANCE TO DOXORUBICIN 505
antagonists, was related to their ability to inhibit
the high affinity binding of [3H]-Nitrendipine
(another calcium antagonist) to these membranes.
However, specific calcium-dependent binding of
[3H]-Nitrendipine could not be demonstrated in
membranes prepared from either P388 or
P388/ADR cells (Dr R. Fine, Personal
Communication). Also, if the doxorubicin
synergistic effect of the compounds tested was
indeed related to their blocking activity of calcium
channels, one would also expect that their potency
as doxorubicin synergists would be in the following
order: lanthanum > perhexilin > chlorcyclizine >
chloroquine > phentolamine > guanethidine >
verapamil (Table III). However, the data presented
in Tables I and II and in our previous study (Ramu
et al., 1984b) suggest that this is not the case. This
lack of correlation can also be demonstrated by
comparing the doxorubicin synergistic activity of
the so called calcium channel antagonists (Tsuruo
et al., 1983b), with their activity in blocking calcium
channels (Fleckenstein, 1977; Lee & Tsien, 1983;
Triggle, 1981, 1982).
As is shown in Tables I and II, nifedipine, unlike
its structural analogue, nicardipine, has only a
minimal doxorubicin synergistic activity. Similar
results were obtained by others (Table III in
Tsuruo et al., 1983a). It is therefore suggested that
the 2-(N-benzyl)-N-methylamino-ethyl moiety of
the nicardipine is important for the doxorubicin
synergistic activity of this drug. A similar structure
can be found in meclizine, verapamil and more
remotely in dipyridamol, perhexiline, chlorcyclizine,
thioridazine, and MDL 6792.
In the present study, thioridazine was found to
have a moderate synergism to doxorubicin in the
P388/ADR cell line. Similar results were obtained
with other phenothiazines (Tsuruo et al., 1982;
Ganapathi & Grabowski, 1983; Inaba et al., 1981).
Recently, Kauffman & Conery (1983) have
demonstrated that thioridazine and some other
phenothiazines were effective inhibitors of the
binding of [3H]-Nitrendipine to cardiac muscle cell
membranes. However, as previously discussed, this
characteristic does not seem related to the
restoration of sensitivity to doxorubicin in drug-
resistant cells. There were also suggestions that the
phenothiazines exert some of their pharmacological
effects by blocking the calmodulin mediated
activities (Weiss et al., 1980). Subsequently it was
suggested that the inhibition of the action of
calmodulin is related to the synergism of these
compounds with doxorubicin (Tsuruo et al., 1982).
In fact the ability to bind calmodulin and/or block
its activities was also shown for some other
doxorubicin synergistic compounds like verapamil,
prenylamine, dilthiazem, nicardipine, nimodipine,
dibucaine, propranolol and phentolamine (Johnson,
1983a,b; Epstein et al., 1982; Tsuruo et al., 1982;
Volpi et al., 1981; Earl et al., 1982). However, as in
the case of calcium channel blockade, there is no
correlation between the potencies of these drugs in
inhibiting calmodulin-mediated effects and their
activity in restoring the sensitivity of drug-resistant
cells to doxorubicin. These and other drugs which
were shown to antagonize calmodulin-induced
activities are of a wide range of chemical classes
and have a wide spectrum of pharmacological
activities (Vincenzi, 1982). It was suggested that a
feature common to all these agents is that they are
amphipathic and cationic at physiological pH, and
that their binding to calmodulin is not particularly
specific (Vincenzi, 1981). These amphipathic
cationic compounds can share other activities that
are not calmodulin dependent (Vincenzi et al.,
1982). More relevant, perhaps, is the recent
observation that the calmodulin inhibitory activity
of many compounds is related to their ability to
stabilize the erythrocyte membrane (Bereza et al.,
1982). It is therefore suggested that the doxorubicin
synergistic activity of these compounds is related to
their interaction with the cell membrane rather than
to calcium channel blockade or to inhibition of
calmodulin mediated drug efflux. In our previous
studies (Ramu et al., 1983; 1984c), major
differences were found in the characteristics of the
lipid domains of the plasma membrane of
P388/ADR cells compared to those of the parent
P388 cell line. Therefore the preferential
enhancement, by these compounds, of the
doxorubicin cytotoxicity in P388/ADR cells, may
further indicate that specific interaction with the
cell membrane lipid domain, is related to the
doxorubicin synergistic activity.
The present results indicate that certain drugs
restore the effectiveness of doxorubicin against
resistant cells in vitro. They imply that concomitant
administration of these drugs in patients may result
in enhanced chemotherapeutic activity of
doxorubicin in refractory patients. The finding that
the increase in doxorubicin potency was not
observed in drug sensitive cells suggest that the
synergism may be limited to the drug-resistant cells.
However, prior to clinical trials, in vitro studies
demonstrating no decrease in the therapeutic index
of doxorubicin in the presence of these drugs are
needed.
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